1. Home >
  2. M&A >
  3. Recapitalization >
  4. Ampersand Capital Partners Acquires P95

M&A Deal Summary

Ampersand Capital Partners Acquires P95

On May 2, 2023, growth capital firm Ampersand Capital Partners acquired life science company P95

Acquisition Highlights
  • This is Ampersand Capital Partners’ 38th transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 1st transaction in Belgium.

M&A Deal Summary
Date 2023-05-02
Target P95
Sector Life Science
Buyer(s) Ampersand Capital Partners
Deal Type Recapitalization

Target

P95

Leuven, Belgium
P95 is a global provider of clinical and epidemiology research solutions with a specialty focus on vaccines and infectious diseases. P95 offers a wide range of solutions including phase I-IV clinical studies, epidemiology, and RWE studies, in addition to scientific and clinical development consulting. It provides end-to-end services including study start-up, clinical monitoring, sample management, medical monitoring and pharmacovigilance, qualitative research, medical writing, data management, biostatistics, and IT. P95 was founded in 2011 and is based in Leuven, Belgium.

Search 206,096 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 77 of 85
Sector: Life Science M&A 38 of 43
Type: Recapitalization M&A Deals 6 of 7
Country: Belgium M&A 1 of 1
Year: 2023 M&A 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-11-08 Alcami

Wilmington, North Carolina, United States

Alcami is a fully-integrated end-to-end contract development and manufacturing organization. Alcami serves pharmaceutical and biotech companies of all sizes providing customizable and innovative solutions for analytical development, clinical to commercial sterile and oral solid manufacturing, packaging, microbiology, cGMP biostorage, environmental monitoring, and pharmaceutical support services. Alcami was founded in 1979 and is based in Wilmington, North Carolina.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-06-12 NanoImaging Services

San Diego, California, United States

NanoImaging Services provides imaging services to the pharmaceutical, biotechnology, and nanotechnology communities. The company is committed to expanding its service capacity through microscope acquisition, workflow automation, recruitment and training of top talent, and development of new service offerings. Its state-of-the-art facilities include a range of electron microscopes, sample preparation equipment, and computational infrastructure to support structural biology and nanoparticle characterization workflows. NanoImaging Services was formed in 2007 and is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal